We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Alliance Pharma Plc | LSE:APH | London | Ordinary Share | GB0031030819 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.30 | 0.83% | 36.60 | 36.30 | 37.40 | 36.65 | 36.10 | 36.10 | 549,476 | 16:35:22 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 167.42M | 936k | 0.0017 | 214.41 | 196.88M |
Date | Subject | Author | Discuss |
---|---|---|---|
07/8/2015 13:18 | 121,341 shares just bought at 61.5p - a full 1p above the published 60.5p offer price.... | rivaldo | |
06/8/2015 12:36 | Hardman have just released their monthly research summary for August. There's a brief summary of APH's trading update - nothing new, but the inbvestment summary is a useful précis: "Investment summary and share performance: The share price has performed very strongly over the past month, rising 36% and underpinned by above-average trading volumes, as the market reflected on the trading statement and future outlook for growth. Trading on FY15 prospective PE of 16.7x with a 2014-2018 EPS CAGR estimate of 10%, EV/EBITDA of 12.1x with a FCF yield of 6.1%. The dividend yield is 1.9% and 3.1x covered. Interim results are due to be released on 9th September." | rivaldo | |
04/8/2015 11:16 | Maz, suspect it's a combination of Robbie Burns buying in, Ashton & Parsons increased contribution and imminent resumption of Immucyst. Throw in rumours of new products being added - I haven't heard anything, just a guess. I remember commenting on here (maybe 12-18 months ago) that the products they are buying has shifted subtlety - e.g. Lypsol is a well known brand - I'm sure we will have all used at it some stage, and Ashton & Parsons has had years of pent-up demand (and is well-respected I believe) due to production constraints, which has now only just started to be resolved. If they decide to market these brands and export - e.g. A&P to China for example? then clearly it's a huge opportunity for them to build a brand that would be less sensitive to competition from generics. Just a thought though - like you, I am surprised by the scale of the rise. Maybe they've been undervalued for too long?! | cisk | |
04/8/2015 10:51 | Certainly not me and I remain very puzzled as to why we have not had an RNS concerning any change of major share holding. It rather suggests current demand is created by new 'punters' attracted to the rise. I really have no idea, its been quite a phenomenal rise over the last 5 weeks and 'barely stopped for breath' on the way. | mazarin | |
04/8/2015 10:41 | 60p now to buy - who would have thought, a month ago? | pimpernel4 | |
03/8/2015 12:21 | Continued buying coming in, now at 58.48p. | rivaldo | |
31/7/2015 19:02 | Getting heady. | capercaillie | |
31/7/2015 09:16 | Continuing buying pressure at rising prices, the latest being 10k at 56p. | rivaldo | |
30/7/2015 15:35 | wow QP. also ready to pop north | albanyvillas | |
30/7/2015 14:27 | APH are presenting in London on 12th August - a good opportunity to quiz the CEO on what's happening.... | rivaldo | |
27/7/2015 13:50 | Another stream of buys today, including now at 54.5p. Perhaps another acquisition/deal is on the way. | rivaldo | |
24/7/2015 17:39 | APH has held up surprisingly well over the 2 weeks following several small intra-day dips as 'profit-taking' inevitably occurred. It may be worth remembering that APH steadily declined to below 34p in March this year before staging a dramatic recovery and todays share price represents a hefty 53% gain on that position. So many 'shorter term' holders may find current levels hard to ignore. So far there has appeared to be a buyer or buyers in the back ground who were prepared to 'mop up' and reinstate the rising trend, but IMV this situation can't last indefinitely. APH has seen many significant 'breakouts' in the past that have fizzled out for one reason or another and the share price drifted back down for want of news etc. As a long term holder I am keen to know exactly what lies behind the latest move upwards as the prospects for APH in March were just as valid then as they are now. The latest share price surge could well draw comment from analysts. | mazarin | |
23/7/2015 14:09 | Nice 94k buy at 53p early this morning, a full 1p above the 52p offer price at the time. Very keen. | rivaldo | |
22/7/2015 07:30 | Comment from Robbie Burns last week will have helped the price no doubt: Alliance Pharma (APH) looks an interesting pharma with a good pipeline. It didn't have a very good 2014 but statements but recent statements show a much more bullish tone for 2015 and 2016 and the price is rising nicely in response. Obviously pharmas do carry some risk but I like the risk-reward ratio here and happy to pick some up. It's one of those that could be a massive winner given time. It seems to have a winner in Hydromol performing well. | cisk | |
21/7/2015 18:17 | Very good run on this - suddenly in play. | capercaillie | |
21/7/2015 10:31 | I have not seen such positive and sustained 'action' here before without grounds or any news' supportive feed and am equally surprised that no RNS has been issued to indicate change of Interest or Holding. | mazarin | |
21/7/2015 10:31 | This share price action is either Mr Market getting overly excited or APH have lined up another GBP50-100m type deal that I understand was on previously on the cards but never got to the finish line. Such a transformational deal could make 50p look cheap. Guess we will have to wait and see... | norbert colon | |
21/7/2015 09:38 | APH now bid as you like at the mid-price. Only 2000 on offer on the rsp. Looks like another leg up is on the cards. GLA | roper | |
20/7/2015 11:17 | Good summary Norbert in post 571, nothing to add really. Buying coming in at 49p now. | rivaldo | |
15/7/2015 10:18 | Whatever it is, there is no denying that there is a buyer about willing to pay current, rising prices - a buyer who clearly recognises value to be unlocked even from these all time high prices. Congratulations to the company and all patient holders. | pimpernel4 | |
15/7/2015 10:13 | Thanks Norbert, I essentially see it the same way and have real expectation that ImmuCyst in particular has the potential to make quite a contribution to the figures when full production resumes. Its sudden loss a few years ago following Sinofi's disaster certainly had a significant impact on APH's profits and it looks like that's behind them now. However I do appreciate that APH has to recover some of its lost market share from competitors who moved in to fill the gap. | mazarin | |
15/7/2015 08:38 | Maz My thoughts on the price rise / re-rating: - Seen as a growth share again after last few years malaise - ImmuCyst coming back on line after a long wait - profitable product - More deals likely - possibly a big(ger) one - Possibility of being a bid target themselves All of that said, the strong re-rating has come as a surprise but thats Mr Market for you - exuberance / depression - repeat. | norbert colon |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions